(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing
CD3 binding T-cell engagement
Background
Claudin 18.2 (CLDN18.2), a tetraspanin family member essential for the formation of tight junctions,1 is highly expressed in gastric, pancreatic and esophageal adenocarcinomas, with physiological expression restricted to gastric mucosal epithelial cells.2 CLDN18.2 is a validated therapeutic target; zolbetuximab, a CLDN18.2-directed monoclonal antibody, demonstrated clinical benefit in combination with chemotherapy in CLDN18.2-high gastric cancer.3 4 Similarly, CLDN18.2-targeting chimeric antigen receptor T cells and antibody-drug conjugates have shown efficacy in gastric cancers,5–7 and other modalities, including T cell-engagers (TCE), are also in clinical development. Here we describe AZD5863, a CLDN18.2 and cluster of differentiation 3 (CD3)-targeting TCE designed with bivalent high-affinity binding to CLDN18.2 and monovalent low-affinity binding to CD3 to reduce class-associated toxicities, such as cytokine release syndrome, while maintaining potent and specific antitumor activity.
Related products
Catalogue product
Customized product
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate